Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   BioPharma   /   INSM - Insmed - Deel 16

BioPharma« Terug naar discussie overzicht

INSM - Insmed - Deel 16

Volgen
1.439 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 72 »» | Laatste | Omlaag ↓
  1. [verwijderd] 26 februari 2008 17:53
    Zucht. Ik heb mijn insmetjes al zo'n kleine 3 jaar op de plank liggen en zit er al in (schrik niet) vanaf 2.37 per aandeel (tegen de toenmalige dollarkoers, dus kun je nagaan wat een hyperinflatie nu). Het lijkt onwaarschijnlijk dat we ooit nog eens een keertje op het oude niveau komen. Ik zal mijn Mustang nog 'even' moeten uitstellen. Er zit gewoon geen schot in dit aandeel ondanks de soms aangegeven verwachtingen. Dat is jammer want het ontneemt de motivatie om veel te traden hierin. Die centenkwestie tot nu toe schiet niet erg op. Maar we blijven gematigd optimischisch. Erg veel lager dan nu zal hi wel niet gaan.

  3. [verwijderd] 26 februari 2008 21:13
    Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics


    RICHMOND, Va., Feb. 11 /PRNewswire-FirstCall/ -- A report released
    today, commissioned by Insmed Inc. (Nasdaq: INSM), identifies potential
    cost savings of approximately $378 billion over the next 20 years from
    making follow on biologics (FOBs) available in the U.S.

    The econometric study by economist Dr. Robert J. Shapiro, former Under
    Secretary of Commerce in the Clinton Administration, found that "...generic
    versions of the top 12 categories of biologic treatments with patent
    protections that have expired or that are due to expire in the near future
    could save Americans $67 billion to $108 billion over 10 years and $236
    billion to $378 billion over 20 years."

    According to other published reports, an estimated $10 billion worth of
    biologic drugs are expected to come off patent by 2010, with an additional
    $10 billion by 2015. FOBs would provide safe and effective therapies at a
    reduced cost following the expiration of the original product's patent.

    Dr. Shapiro's report, entitled The Potential American Market for
    Generic Biological Treatments and the Associated Cost Savings, also finds
    that "...the economic and medical benefits from generic biologics should be
    as great or perhaps even greater as those from generic forms of traditional
    pharmaceuticals... Moreover, the potential savings from the discounted
    prices that generics provide will be larger with biogenerics, because
    original biologics are so much more expensive than other brand
    pharmaceuticals..."

    The scientific, regulatory and legal framework for the approval of
    small- molecule generic drugs is well developed, and a regulatory system
    for approving FOBs was established in Europe in 2006. However, no
    regulatory pathway currently exists for FOBs, which are also commonly
    referred to as biosimilars or biogenerics, in the U.S.

    "Dr. Shapiro's comprehensive analysis presents a compelling case for
    the need for Congress to adopt legislation so patients can receive
    affordable access to life-saving biotech drugs in a timely manner," said
    Geoffrey Allan, CEO of Insmed, a developer of follow-on biologics and
    biopharmaceuticals. "The cost savings to the health care system have the
    potential to be enormous, while the environment for new market participants
    could introduce competition to these monopolistic markets, similar to that
    seen in the traditional pharmaceutical generics industry."

    The release of Dr. Shapiro's report is part of Insmed's broad education
    campaign on the importance of establishing a regulatory pathway in the U.S.
    for large molecule protein-based drugs, known as follow-on biologics
    (FOBs), which are also commonly referred to as biosimilars or biogenerics.

    Insmed is currently developing a portfolio of FOBs and intends to
    initiate clinical trials for its first two FOBs in 2008. Members of
    Insmed's skilled biologics team have worked on over 50 therapeutic
    proteins. Their focused protein-based drug development backgrounds, coupled
    with the Company's FDA- approved protein manufacturing facility, and
    clinical and regulatory expertise, positions Insmed, upon the establishment
    of a regulatory pathway, to be an initial entrant into the U.S. FOBs market
    with a broad range of medicines following the expiration of patents
    covering the innovator products.

  8. [verwijderd] 28 februari 2008 15:25
    Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market

    Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that on February 27, 2008, it received a letter from the Nasdaq Listings Qualifications Panel (the "Panel") stating that the Panel has determined to transfer the listing of the Company's shares from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the open of the market on Friday, February 29, 2008. The Nasdaq Capital Market is one of the three market tier designations for Nasdaq-listed stock, and presently includes over 500 companies. The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market. It is not related to, nor does it operate similarly to the over-the-counter markets, including the OTCBB and Pink Sheets. Securities listed on the Nasdaq Capital Market satisfy all applicable qualification requirements for Nasdaq securities and all companies listed on the Nasdaq Capital Market must meet certain financial requirements and adhere to Nasdaq's corporate governance standards. Insmed's trading symbol will remain "INSM."

  10. [verwijderd] 28 februari 2008 15:52
    quote:

    DoDD666 schreef:

    Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market

    Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that on February 27, 2008, it received a letter from the Nasdaq Listings Qualifications Panel (the "Panel") stating that the Panel has determined to transfer the listing of the Company's shares from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the open of the market on Friday, February 29, 2008. The Nasdaq Capital Market is one of the three market tier designations for Nasdaq-listed stock, and presently includes over 500 companies. The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market. It is not related to, nor does it operate similarly to the over-the-counter markets, including the OTCBB and Pink Sheets. Securities listed on the Nasdaq Capital Market satisfy all applicable qualification requirements for Nasdaq securities and all companies listed on the Nasdaq Capital Market must meet certain financial requirements and adhere to Nasdaq's corporate governance standards. Insmed's trading symbol will remain "INSM."

    Do,

    Als insmed weer boven een dollar komt voor juni, komen ze dan ook weer in aanmerking voor de global market. Weet iemand hoe dit werkt?
  12. [verwijderd] 28 februari 2008 17:37
    quote:

    gismo74 schreef:

    [quote=DoDD666]
    Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market

    Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that on February 27, 2008, it received a letter from the Nasdaq Listings Qualifications Panel (the "Panel") stating that the Panel has determined to transfer the listing of the Company's shares from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the open of the market on Friday, February 29, 2008. The Nasdaq Capital Market is one of the three market tier designations for Nasdaq-listed stock, and presently includes over 500 companies. The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market. It is not related to, nor does it operate similarly to the over-the-counter markets, including the OTCBB and Pink Sheets. Securities listed on the Nasdaq Capital Market satisfy all applicable qualification requirements for Nasdaq securities and all companies listed on the Nasdaq Capital Market must meet certain financial requirements and adhere to Nasdaq's corporate governance standards. Insmed's trading symbol will remain "INSM."

    [/quote]

    Do,

    Als insmed weer boven een dollar komt voor juni, komen ze dan ook weer in aanmerking voor de global market. Weet iemand hoe dit werkt?
    Ja, moet je wel verzoeken dan
  15. [verwijderd] 28 februari 2008 21:08
    Hoi
    Er is een serieuze belegger die een vraag stelt en niemand geeft antwoord (greg_0 )
    Ik roep maar wat heeft het nog nooit mee gemaakt een delisting of een plaatsing op een andere beursvloer

    graag een uitleg
    Alvast bedankt

    quote:

    crackedtooth schreef:

    zit je nu met onzin te stangen wishboontje?

  20. [verwijderd] 2 maart 2008 13:32
    quote:

    junkbond schreef:

    Third Quarter Financial Results.Kunnen we niet meer beluisteren. Zal wel niets om het lijf hebben ,maar ik vind het wel een beetje vreemd

    www.vcall.com/IC/CEPage.asp?ID=122270

    nee, dat is normaal.. max 90 dagen ofzo erna

    MAAR
    www.xs4all.nl/~surg3on/INSM/

    en dan vooral:
    www.xs4all.nl/~surg3on/INSM/INSM.2007...

    veel plezier ermee

    EN OOK: waarschijnlijk 10-15 maart de ALS igf1 resultaten van de mayo trial
1.439 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 72 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
B&S Group SA 4,395 +0,34 +8,25%
Galapagos 25,380 +1,42 +5,93%
EBUSCO HOLDING 0,925 +0,05 +5,16%
ALLFUNDS GROUP 5,430 +0,27 +5,13%
BESI 112,800 +5,30 +4,93%
THEON INTERNAT 10,340 +0,48 +4,87%
RENEWI 7,150 +0,24 +3,47%
UNILEVER PLC 56,440 +1,88 +3,45%
RELX 44,820 +1,42 +3,27%
FASTNED 21,300 +0,65 +3,15%
Pharming 0,716 +0,02 +3,02%
Wolters Kluwer 157,950 +4,60 +3,00%
WDP 20,720 +0,60 +2,98%
UMG 22,580 +0,63 +2,87%
CTP 15,100 +0,40 +2,72%
DSM FIRMENICH AG 107,250 +2,40 +2,29%
INPOST 17,210 +0,35 +2,08%
SIGNIFY NV 21,740 +0,44 +2,07%
IMCD 140,150 +2,80 +2,04%
Eurocommercial Properties 23,300 +0,45 +1,97%
Fagron 18,620 +0,34 +1,86%
ADYEN NV 1.290,400 +23,40 +1,85%
ASML 642,100 +10,60 +1,68%
ASMI 504,600 +8,20 +1,65%
Ahold Delhaize 32,830 +0,52 +1,61%
AEX 879,80 +13,67 +1,58%
Kendrion 10,900 +0,16 +1,49%
JDE PEET'S 18,600 +0,23 +1,25%
OCI 11,315 +0,13 +1,16%
Heineken 70,640 +0,76 +1,09%
ACOMO 17,640 +0,18 +1,03%
Sif Holding 12,220 +0,12 +0,99%
AMX 866,26 +8,37 +0,98%
NX FILTRATION 4,240 +0,04 +0,95%
Avantium 2,170 +0,02 +0,93%
EXOR NV 95,200 +0,85 +0,90%
Brunel 8,470 +0,07 +0,83%
ASCX 1.183,15 +9,48 +0,81%
RANDSTAD NV 40,610 +0,31 +0,77%
Nedap N.V. 52,400 +0,40 +0,77%
Philips Koninklijke 25,220 +0,19 +0,76%
Sligro 10,660 +0,08 +0,76%
Corbion 21,980 +0,16 +0,73%
Arcadis 62,200 +0,45 +0,73%
AALBERTS NV 34,100 +0,22 +0,65%
ASR Nederland 45,130 +0,29 +0,65%
Vastned 24,250 +0,15 +0,62%
Wereldhave 14,120 +0,08 +0,57%
KPN 3,620 +0,02 +0,56%
Aegon 5,960 +0,03 +0,51%
TomTom 5,200 +0,03 +0,48%
Akzo Nobel 55,880 +0,26 +0,47%
ArcelorMittal 23,990 +0,08 +0,33%
SHELL PLC 31,610 +0,09 +0,27%
NSI 19,700 +0,04 +0,20%
Accsys 0,555 +0,00 +0,18%
HEIJMANS KON 27,950 +0,05 +0,18%
Fugro 16,900 +0,03 +0,18%
AMG Critical Materials N.V. 14,980 +0,01 +0,07%
PostNL 1,009 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
EBUSCO (RIGHT) 0,000 -0,16 -99,81%
SBM Offshore 17,720 -0,30 -1,66%
CM.COM 6,000 -0,10 -1,64%
JUST EAT TAKEAWAY 14,010 -0,23 -1,58%
Alfen N.V. 11,245 -0,17 -1,45%
Vopak 45,100 -0,60 -1,31%
Flow Traders 21,380 -0,28 -1,29%
BAM 4,010 -0,05 -1,23%
ING 14,652 -0,17 -1,16%
ForFarmers 3,280 -0,03 -0,91%
Van Lanschot Kempen NV 43,100 -0,35 -0,81%
ABN AMRO BANK N.V. 14,735 -0,12 -0,77%
AZERION 1,266 -0,01 -0,63%
Air France-KLM 7,358 -0,05 -0,62%
TKH 31,720 -0,18 -0,56%
NN Group 44,640 -0,20 -0,45%
Basic-Fit 21,500 -0,08 -0,37%
PROSUS 37,970 -0,13 -0,35%
Aperam 27,560 -0,06 -0,22%
vlag naam koers verschil relatief verschil
AEX 879,80 +13,67 +1,58%
AEX GR 3.450,86 +53,61 +1,58%
Germany40^ 19.354,60 +208,43 +1,09%
FTSE 100 8.262,08 +112,81 +1,38%
EURO50 4.797,55 0,00 0,00%
US30^ 44.302,90 0,00 0,00%
Nasd100^ 20.778,50 0,00 0,00%
US500^ 5.965,55 0,00 0,00%
Japan225^ 38.598,50 0,00 0,00%
VD-NEW 16,06 -0,99 -5,82%
#/^ Index indications calculated real time, zie disclaimer